Literature DB >> 23429058

Comprehensive interrogation of a minimalist synthetic CDR-H3 library and its ability to generate antibodies with therapeutic potential.

Ciara M Mahon1, Matthew A Lambert, Jacob Glanville, Jason M Wade, Brian J Fennell, Mark R Krebs, Douglas Armellino, Sharon Yang, Xuemei Liu, Cliona M O'Sullivan, Benedicte Autin, Katarzyna Oficjalska, Laird Bloom, Janet Paulsen, Davinder Gill, Marc Damelin, Orla Cunningham, William J J Finlay.   

Abstract

We have generated large libraries of single-chain Fv antibody fragments (>10(10) transformants) containing unbiased amino acid diversity that is restricted to the central combining site of the stable, well-expressed DP47 and DPK22 germline V-genes. Library WySH2A was constructed to examine the potential for synthetic complementarity-determining region (CDR)-H3 diversity to act as the lone source of binding specificity. Library WySH2B was constructed to assess the necessity for diversification in both the H3 and L3. Both libraries provided diverse, specific antibodies, yielding a total of 243 unique hits against 7 different targets, but WySH2B produced fewer hits than WySH2A when selected in parallel. WySH2A also consistently produced hits of similar quality to WySH2B, demonstrating that the diversification of the CDR-L3 reduces library fitness. Despite the absence of deliberate bias in the library design, CDR length was strongly associated with the number of hits produced, leading to a functional loop length distribution profile that mimics the biases observed in the natural repertoire. A similar trend was also observed for the CDR-L3. After target selections, several key amino acids were enriched in the CDR-H3 (e.g., small and aromatic residues) while others were reduced (e.g., strongly charged residues) in a manner that was specific to position, preferentially occurred in CDR-H3 stem positions, and tended towards residues associated with loop stabilization. As proof of principle for the WySH2 libraries to produce viable lead candidate antibodies, 114 unique hits were produced against Delta-like ligand 4 (DLL4). Leads exhibited nanomolar binding affinities, highly specific staining of DLL4+ cells, and biochemical neutralization of DLL4-NOTCH1 interaction.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429058     DOI: 10.1016/j.jmb.2013.02.015

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  27 in total

1.  Augmented Binary Substitution: Single-pass CDR germ-lining and stabilization of therapeutic antibodies.

Authors:  Sue Townsend; Brian J Fennell; James R Apgar; Matthew Lambert; Barry McDonnell; Joanne Grant; Jason Wade; Edward Franklin; Niall Foy; Deirdre Ní Shúilleabháin; Conor Fields; Alfredo Darmanin-Sheehan; Amy King; Janet E Paulsen; Timothy P Hickling; Lioudmila Tchistiakova; Orla Cunningham; William J J Finlay
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-30       Impact factor: 11.205

2.  Understanding differences between synthetic and natural antibodies can help improve antibody engineering.

Authors:  Anat Burkovitz; Yanay Ofran
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

3.  Scalable high throughput selection from phage-displayed synthetic antibody libraries.

Authors:  Shane Miersch; Zhijian Li; Rachel Hanna; Megan E McLaughlin; Michael Hornsby; Tet Matsuguchi; Marcin Paduch; Annika Sääf; Jim Wells; Shohei Koide; Anthony Kossiakoff; Sachdev S Sidhu
Journal:  J Vis Exp       Date:  2015-01-17       Impact factor: 1.355

4.  BCR selection and affinity maturation in Peyer's patch germinal centres.

Authors:  Huan Chen; Yuxiang Zhang; Adam Yongxin Ye; Zhou Du; Mo Xu; Cheng-Sheng Lee; Joyce K Hwang; Nia Kyritsis; Zhaoqing Ba; Donna Neuberg; Dan R Littman; Frederick W Alt
Journal:  Nature       Date:  2020-05-06       Impact factor: 49.962

5.  A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv).

Authors:  Chao Tu; Virginie Terraube; Amy Sze Pui Tam; Wayne Stochaj; Brian J Fennell; Laura Lin; Mark Stahl; Edward R LaVallie; Will Somers; William J J Finlay; Lydia Mosyak; Joel Bard; Orla Cunningham
Journal:  J Biol Chem       Date:  2015-10-29       Impact factor: 5.157

Review 6.  Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering.

Authors:  Cristina Parola; Daniel Neumeier; Sai T Reddy
Journal:  Immunology       Date:  2017-10-30       Impact factor: 7.397

Review 7.  Deep sequencing methods for protein engineering and design.

Authors:  Emily E Wrenbeck; Matthew S Faber; Timothy A Whitehead
Journal:  Curr Opin Struct Biol       Date:  2016-11-22       Impact factor: 6.809

8.  ScaffoldSeq: Software for characterization of directed evolution populations.

Authors:  Daniel R Woldring; Patrick V Holec; Benjamin J Hackel
Journal:  Proteins       Date:  2016-04-16

Review 9.  Selecting and engineering monoclonal antibodies with drug-like specificity.

Authors:  Charles G Starr; Peter M Tessier
Journal:  Curr Opin Biotechnol       Date:  2019-02-26       Impact factor: 9.740

Review 10.  Deep sequencing in library selection projects: what insight does it bring?

Authors:  J Glanville; S D'Angelo; T A Khan; S T Reddy; L Naranjo; F Ferrara; A R M Bradbury
Journal:  Curr Opin Struct Biol       Date:  2015-08       Impact factor: 6.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.